Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?

Am J Hematol. 2017 May;92(5):E72-E74. doi: 10.1002/ajh.24686. Epub 2017 Mar 22.

Authors

Federico De Marchi^{1

2}, Anna Candoni¹, Maria Elena Zannier¹, Lisa Haley², Bonnie Wing Yin Lau³, Renato Fanin¹

Affiliations

¹ Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
² Department of Pathology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, MD, 21287, USA.
³ Department of Pediatric Hematology/Oncology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, MD, 21287, USA.

PMID: 28211167
DOI: 10.1002/ajh.24686

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor* / genetics
Biomarkers, Tumor* / metabolism
Disease-Free Survival
Female
Gene Expression Regulation, Leukemic*
Humans
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / mortality
Male
Mutation*
Neoplasm, Residual
Survival Rate
WT1 Proteins* / genetics
WT1 Proteins* / metabolism
fms-Like Tyrosine Kinase 3* / genetics
fms-Like Tyrosine Kinase 3* / metabolism

Substances

Biomarkers, Tumor
WT1 Proteins
WT1 protein, human
FLT3 protein, human
fms-Like Tyrosine Kinase 3